Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

Joseph Bratica Biography and Net Worth

Insider of Sarepta Therapeutics

Currently, Joseph Bratica is VP, Controller, CFO & Chief Accounting Officer at Sarepta Therapeutics, Inc.

In his past career Mr. Bratica was Vice President-Finance & Controller at ARIAD Pharmaceuticals, Inc. and Accounting Manager at Creative Biomolecules, Inc.

He received an undergraduate degree from Suffolk University.

What is Joseph Bratica's net worth?: The estimated net worth of Joseph Bratica is at least $1.02 million as of December 11th, 2020. Mr. Bratica owns 9,255 shares of Sarepta Therapeutics stock worth more than $1,015,366 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Bratica may own. Learn More about Joseph Bratica's net worth.
How do I contact Joseph Bratica?: The corporate mailing address for Mr. Bratica and other Sarepta Therapeutics executives is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. Sarepta Therapeutics can also be reached via phone at (617) 274-4000 and via email at [email protected]. Learn More on Joseph Bratica's contact information.
Has Joseph Bratica been buying or selling shares of Sarepta Therapeutics?: Joseph Bratica has not been actively trading shares of Sarepta Therapeutics during the past quarter. Most recently, Joseph Bratica sold 1,115 shares of the business's stock in a transaction on Friday, December 11th. The shares were sold at an average price of $165.00, for a transaction totalling $183,975.00. Following the completion of the sale, the insider now directly owns 9,255 shares of the company's stock, valued at $1,527,075. Learn More on Joseph Bratica's trading history.
Who are Sarepta Therapeutics' active insiders?: Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?: In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 9 times. They sold a total of 78,532 shares worth more than $11,647,905.42. The most recent insider tranaction occured on August, 30th when CFO Ian Michael Estepan sold 5,985 shares worth more than $822,099.60. Insiders at Sarepta Therapeutics own 7.7% of the company. Learn More about insider trades at Sarepta Therapeutics.
Information on this page was last updated on 8/30/2024.

Joseph Bratica Insider Trading History at Sarepta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/11/2020	Sell	1,115	$165.00	$183,975.00	9,255
12/8/2020	Sell	1,125	$160.00	$180,000.00
8/3/2020	Sell	1,125	$155.00	$174,375.00	8,957

Joseph Bratica Buying and Selling Activity at Sarepta Therapeutics

Sarepta Therapeutics Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $109.71

$109.26

$110.20

50 Day Range

MA: $122.50

$104.54

$132.02

2 Week Range

Now: $109.71

$78.67

$173.25

Volume

17,157 shs

Average Volume

1,228,453 shs

Market Capitalization

$10.48 billion

P/E Ratio

87.77

Dividend Yield

N/A

Beta

0.81

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

From Darwin | Ad

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!